Details:

Alternative Title:
MMWR. Morbidity and mortality weekly report
Corporate Authors:
United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ;
United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; Less -
Description:
On June 20, 2008 the Food and Drug Administration (FDA) licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), inactivated poliovirus vaccine (IPV), and Haemophilus influenzae type b conjugate (tetanus toxoid [TT] conjugate) vaccine, DTaP-IPV/Hib (Pentacel, Sanofi Pasteur, Swiftwater, Pennsylvania), for use as a four-dose series in infants and children at ages 2, 4, 6, and 15-18 months. This report summarizes the indications for Pentacel and provides guidance from the Advisory Committee on Immunization Practices (ACIP) for its use.
Subject:
[+]
Child, Preschool
Diphtheria-Tetanus-acellular Pertussis Vaccines
Diphtheria-Tetanus-Pertussis Vaccine
Haemophilus Vaccines
Humans
Immunization Schedule
Infant
Licensure
Poliovirus Vaccine, Inactivated
Vaccines, Combined

Source:
MMWR. Morbidity and mortality weekly report. 2008; 57(39):1079-80.
Pubmed ID:
18830213
Document Type:
Journal Article ;
Place as Subject:
United States ;
Collection(s):
Guidelines and Recommendations
Advisory Committee on Immunization Practices (ACIP)
Main Document Checksum:
[+]
urn:sha256:24865027db75e45262c9ca2eaf6a948dcaa520b0513a3ce6cc43843ffbbf938c
File Type:

Supporting Files

• No Additional Files

More +